Physician profile
David Goldstein
NPI 1023273190
$2,091.16
in general payments reported to CMS, 2019-2025
25 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $365 · 2021: $232 · 2022: $143 · 2023: $202 · 2024: $304 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $354.77 | 2019-2024 | Mitraclip |
| Janssen Pharmaceuticals, INC | $230.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $177.35 | 2020-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $164.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $157.14 | 2019-2021 | |
| Amgen INC. | $142.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $125.53 | 2023-2024 | Nucala |
| Novo Nordisk INC | $112.20 | 2020-2024 | Ozempic, Wegovy, Rybelsus |
| Daiichi Sankyo INC. | $75.15 | 2023-2024 | Injectafer |
| Lilly USA, LLC | $73.52 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $71.47 | 2024-2025 | Watchman Flx |
| Esperion Therapeutics, INC. | $57.66 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.37 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $53.75 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.84 | 2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $32.33 | 2024 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $30.05 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $23.36 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $23.04 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $21.25 | 2020 | |
| Abbvie INC. | $20.00 | 2021 | |
| Bardy Diagnostics, INC. | $16.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2025 | Glassia |
| Pfizer INC. | $13.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.